The FDA Has Accepted Viatris And Mapi Pharma's New Drug Application For Ga Depot 40 Mg, As A Once-monthly Injection For Relapsing Forms Of Multiple Sclerosis, With PDUF Action Date Of March 8, 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted a new drug application from Viatris and Mapi Pharma for Ga Depot 40 Mg, a once-monthly injection for relapsing forms of multiple sclerosis. The PDUF action date is set for March 8, 2024.
August 07, 2023 | 10:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viatris' new drug application for a multiple sclerosis treatment has been accepted by the FDA. This could potentially boost the company's revenues if the drug is approved.
The acceptance of the new drug application by the FDA is a positive development for Viatris. If the drug is approved, it could potentially lead to increased revenues for the company. However, the PDUF action date is set for 2024, so any potential impact on the company's revenues will not be immediate.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100